Tags

Type your tag names separated by a space and hit enter

Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes.

Abstract

AIMS

Whether adverse effect of statins on glycaemic indices is common to all statins remains controversial and as yet data for pitavastatin are limited. We sought to assess the effects of pitavastatin on glycaemia and new-onset diabetes (NOD) in non-diabetic individuals using data from RCT pooled together by means of a meta-analysis.

MATERIALS AND METHODS

We searched Medline, Cochrane, Embase and clinical trials registries websites until November-2014 for ≥12-week follow-up placebo or statin-controlled RCT of pitavastatin that included participants without diabetes and reported on fasting blood glucose (FBG), HbA1c or NOD. We additionally sought studies by consulting with Kowa Ph. Ltd. The association of pitavastatin with the outcomes were estimated by random-effects meta-analyses. Heterogeneity was assessed by the I(2) statistic and sensitivity and subgroup analyses, and publication bias with funnel plots and Egger and Harbord Tests.

RESULTS

15 studies (approx. 1600 person-years) were included. No significant differences associated with pitavastatin (vs. control) were observed for FBG (MD -0.01 mg/dL [95%CI -0.77, 0.74], I(2) = 0%), HbA1c (MD -0.03% [95%CI -0.11, 0.05], I(2) = 43%) or NOD (RR 0.70 [95%CI 0.30, 1.61]; RD 0.0 [95%CI -0.004, 0.003]; I(2) = 0%). Sensitivity and subgroup analyses (including type of control [placebo or other statin], pitavastatin dose or follow-up] did not yield significant results. Potential publication bias may occur for NOD.

CONCLUSIONS

In the present meta-analysis pitavastatin did not adversely affect glucose metabolism or diabetes development compared with placebo or other statins.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Cardiovascular Sciences, Cardiovascular and Cell Sciences Research Institute, St George's University of London, London, UK.

    ,

    Cardiovascular Sciences, Cardiovascular and Cell Sciences Research Institute, St George's University of London, London, UK.

    ,

    Division of Cardiovascular Medicine, Miyazaki Prefectural Nobeoka Hospital, Japan.

    ,

    Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Japan.

    ,

    Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Japan.

    ,

    Division of Cardiovascular Medicine, Department of Medicine, Faculty of Life Sciences, Graduate School of Medical Science, Kumamoto University, Japan.

    ,

    Division of Cardiovascular Diseases, University of California San Diego, USA.

    ,

    Department of Laboratory Medicine, Jikei University Kashiwa Hospital, Japan.

    Department of Primary Care and Public Health, School of Public Health, Imperial College London, UK. Electronic address: k.ray@imperial.ac.uk.

    Source

    Atherosclerosis 241:2 2015 Aug pg 409-18

    MeSH

    Biomarkers
    Blood Glucose
    Chi-Square Distribution
    Diabetes Mellitus
    Dyslipidemias
    Glycated Hemoglobin A
    Humans
    Hydroxymethylglutaryl-CoA Reductase Inhibitors
    Incidence
    Odds Ratio
    Quinolines
    Randomized Controlled Trials as Topic
    Risk Assessment
    Risk Factors
    Treatment Outcome

    Pub Type(s)

    Journal Article
    Meta-Analysis
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    26074315

    Citation

    Vallejo-Vaz, Antonio J., et al. "Effect of Pitavastatin On Glucose, HbA1c and Incident Diabetes: a Meta-analysis of Randomized Controlled Clinical Trials in Individuals Without Diabetes." Atherosclerosis, vol. 241, no. 2, 2015, pp. 409-18.
    Vallejo-Vaz AJ, Kondapally Seshasai SR, Kurogi K, et al. Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes. Atherosclerosis. 2015;241(2):409-18.
    Vallejo-Vaz, A. J., Kondapally Seshasai, S. R., Kurogi, K., Michishita, I., Nozue, T., Sugiyama, S., ... Ray, K. K. (2015). Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes. Atherosclerosis, 241(2), pp. 409-18. doi:10.1016/j.atherosclerosis.2015.06.001.
    Vallejo-Vaz AJ, et al. Effect of Pitavastatin On Glucose, HbA1c and Incident Diabetes: a Meta-analysis of Randomized Controlled Clinical Trials in Individuals Without Diabetes. Atherosclerosis. 2015;241(2):409-18. PubMed PMID: 26074315.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes. AU - Vallejo-Vaz,Antonio J, AU - Kondapally Seshasai,Sreenivasa Rao, AU - Kurogi,Kazumasa, AU - Michishita,Ichiro, AU - Nozue,Tsuyoshi, AU - Sugiyama,Seigo, AU - Tsimikas,Sotirios, AU - Yoshida,Hiroshi, AU - Ray,Kausik K, Y1 - 2015/06/04/ PY - 2015/02/26/received PY - 2015/05/15/revised PY - 2015/06/02/accepted PY - 2015/6/16/entrez PY - 2015/6/16/pubmed PY - 2016/5/28/medline KW - Diabetes mellitus KW - Glucose KW - Glycated haemoglobin KW - HbA1c KW - Meta-analysis KW - NK-104 KW - Pitavastatin SP - 409 EP - 18 JF - Atherosclerosis JO - Atherosclerosis VL - 241 IS - 2 N2 - AIMS: Whether adverse effect of statins on glycaemic indices is common to all statins remains controversial and as yet data for pitavastatin are limited. We sought to assess the effects of pitavastatin on glycaemia and new-onset diabetes (NOD) in non-diabetic individuals using data from RCT pooled together by means of a meta-analysis. MATERIALS AND METHODS: We searched Medline, Cochrane, Embase and clinical trials registries websites until November-2014 for ≥12-week follow-up placebo or statin-controlled RCT of pitavastatin that included participants without diabetes and reported on fasting blood glucose (FBG), HbA1c or NOD. We additionally sought studies by consulting with Kowa Ph. Ltd. The association of pitavastatin with the outcomes were estimated by random-effects meta-analyses. Heterogeneity was assessed by the I(2) statistic and sensitivity and subgroup analyses, and publication bias with funnel plots and Egger and Harbord Tests. RESULTS: 15 studies (approx. 1600 person-years) were included. No significant differences associated with pitavastatin (vs. control) were observed for FBG (MD -0.01 mg/dL [95%CI -0.77, 0.74], I(2) = 0%), HbA1c (MD -0.03% [95%CI -0.11, 0.05], I(2) = 43%) or NOD (RR 0.70 [95%CI 0.30, 1.61]; RD 0.0 [95%CI -0.004, 0.003]; I(2) = 0%). Sensitivity and subgroup analyses (including type of control [placebo or other statin], pitavastatin dose or follow-up] did not yield significant results. Potential publication bias may occur for NOD. CONCLUSIONS: In the present meta-analysis pitavastatin did not adversely affect glucose metabolism or diabetes development compared with placebo or other statins. SN - 1879-1484 UR - https://www.unboundmedicine.com/medline/citation/26074315/Effect_of_pitavastatin_on_glucose_HbA1c_and_incident_diabetes:_A_meta_analysis_of_randomized_controlled_clinical_trials_in_individuals_without_diabetes_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0021-9150(15)01351-9 DB - PRIME DP - Unbound Medicine ER -